US Stock MarketDetailed Quotes
NGNE Neurogene
- 44.010
- +0.270+0.62%
Close Oct 31 16:00 ET
- 44.010
- 0.0000.00%
Post 16:02 ET
571.85MMarket Cap-15540P/E (TTM)
44.310High42.230Low107.27KVolume43.560Open43.740Pre Close4.68MTurnover2.11%Turnover RatioLossP/E (Static)12.99MShares55.20552wk High3.69P/B223.42MFloat Cap12.49052wk Low--Dividend TTM5.08MShs Float1115.000Historical High--Div YieldTTM4.76%Amplitude7.500Historical Low43.616Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Neurogene Stock Forum
NEWS
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome will be ...
No comment yet